EORTC-1203-GITCG - the “INNOVATION”-trial: Effect of chemotherapy alone versus chemotherapy plus trastuzumab, versus chemotherapy plus trastuzumab plus pertuzumab, in the perioperative treatment of HER2 positive, gastric and gastroesophageal junction adenocarcinoma on pathologic response rate: a randomized phase II-intergroup trial of the EORTC-Gastrointestinal Tract Cancer Group, Korean Cancer Study Group and Dutch Upper GI-Cancer group

BACKGROUND: 10–20% of patients with gastric cancer (GC) have HER2+ tumors. Addition of trastuzumab (T) to cisplatin/fluoropyrimidine-based chemotherapy (CT) improved survival in metastatic, HER2+ GC. When pertuzumab (P) was added to neoadjuvant T and CT, a significant increase in histopathological c...

Descripción completa

Detalles Bibliográficos

Autores principales:	Wagner, Anna Dorothea, Grabsch, Heike I., Mauer, Murielle, Marreaud, Sandrine, Caballero, Carmela, Thuss-Patience, Peter, Mueller, Lothar, Elme, Annelie, Moehler, Markus Hermann, Martens, Uwe, Kang, Yoon-Koo, Rha, Sun Young, Cats, Annemieke, Tokunaga, Masanori, Lordick, Florian
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2019
Materias:	Study Protocol
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6534855/ https://www.ncbi.nlm.nih.gov/pubmed/31126258 http://dx.doi.org/10.1186/s12885-019-5675-4